Table 2.
CACF |
Doxorubicin |
|||
---|---|---|---|---|
IC50 (mean ± SD) μg/mL | IC50 (mean ± SD) μg/mL | |||
|
24 h |
48 h |
24 h |
48 h |
A375 |
9.3 ± 2.5 |
8.5 ± 1.2 |
7.6 ± 0.8 |
6.2 ± 1.5 |
Primary melanocytes | 24.3 ± 4.6 | 21.5 ± 3.1 | 8.5 ± 2.5 | 7.2 ± 2.2 |
CACF |
Doxorubicin |
|||
---|---|---|---|---|
IC50 (mean ± SD) μg/mL | IC50 (mean ± SD) μg/mL | |||
|
24 h |
48 h |
24 h |
48 h |
A375 |
9.3 ± 2.5 |
8.5 ± 1.2 |
7.6 ± 0.8 |
6.2 ± 1.5 |
Primary melanocytes | 24.3 ± 4.6 | 21.5 ± 3.1 | 8.5 ± 2.5 | 7.2 ± 2.2 |